Ocular actions of platelet-activating factor: clinical implications

被引:9
|
作者
Nitoda, Eirini [2 ]
Moschos, Marilita M. [3 ]
Mavragani, Clio P. [1 ]
Koutsilieris, Michael [1 ]
机构
[1] Univ Athens, Sch Med, Dept Expt Physiol, Goudi 11527, Greece
[2] Univ Athens, Sch Med, Dept Ophthalmol, Dept Expt Physiol, Athens 15125, Greece
[3] Univ Athens, Sch Med, Dept Ophthalmol, Athens 14578, Greece
关键词
inflammatory mediators; ocular inflammation; PAF; PAF antagonists; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL ALLERGIC CONJUNCTIVITIS; FACTOR RECEPTOR ANTAGONIST; FACTOR ACETYLHYDROLASE; FACTOR PAF; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; LIPID MEDIATORS; GUINEA-PIGS; PROINFLAMMATORY CYTOKINES;
D O I
10.1517/14728222.2012.712961
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: To summarize the currently available evidence of platelet-activating factor (PAF) implication in the pathogenesis of inflammatory ocular diseases. Areas covered: PAF is a potent mediator of inflammation, implicated in the pathogenesis of chronic inflammatory disorders, allergic reactions, oncogenic transformation, wound repair and hypoxia-induced angiogenesis. It seems to be involved in the protection of ocular surface against various harmful agents through inflammatory processes, which can lead to chronic allergic reactions or even corneal neovascularization and haze, if they do not undergo regulation. Pathogenesis of uveitis, which is significant cause for the blurring of the visual system, has also been associated with PAF's activity. The hypoxia and the breakdown of the blood-retina barrier, observed in severe vascular retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are associated with PAF ocular activity. Expert opinion: Understanding the pathophysiology of vision threatening diseases could enhance clinical treatment and encourage experimental studies, which could be based on potential beneficial effects of new agents, such as PAF antagonists.
引用
收藏
页码:1027 / 1039
页数:13
相关论文
共 50 条
  • [41] Neuroprotection by platelet-activating factor antagonism
    Tian, XH
    Bazan, NG
    NEUROPROTECTIVE AGENTS, 2005, 1053 : 455 - 456
  • [42] Platelet-activating factor and the growth of fibroblasts
    Rougier, F
    Denizot, Y
    MOLECULAR CARCINOGENESIS, 1998, 22 (04) : 221 - 221
  • [43] MODULATION OF THE BIOSYNTHESIS OF PLATELET-ACTIVATING FACTOR
    SUGIURA, T
    UCHIYAMA, A
    MASUZAWA, Y
    FUJITA, M
    NAKAGAWA, Y
    WAKU, K
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 31 - 31
  • [44] IMMUNOMODULATORY PROPERTIES OF PLATELET-ACTIVATING FACTOR
    BRAQUET, P
    HOSFORD, D
    LEUKOTRIENES AND PROSTANOIDS IN HEALTH AND DISEASE, 1989, 3 : 130 - 134
  • [45] CORONARY EFFECTS OF PLATELET-ACTIVATING FACTOR
    BOYD, LM
    EZRA, D
    SNYDER, F
    FEUERSTEIN, G
    GOLDSTEIN, RE
    CIRCULATION, 1983, 68 (04) : 34 - 34
  • [46] Role of platelet-activating factor in parturition
    Narahara, H
    Toyoshima, K
    Johnston, JM
    PLATELET-ACTIVATING FACTOR AND RELATED LIPID MEDIATORS 2: ROLES IN HEALTH AND DISEASE, 1996, 416 : 269 - 275
  • [47] MACROPHAGE ORIGIN OF PLATELET-ACTIVATING FACTOR
    MENCIAHUERTA, JM
    DUVAL, D
    BENVENISTE, J
    COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES SERIE D, 1978, 286 (02): : 241 - 244
  • [48] A SUPERFUSION BIOASSAY FOR PLATELET-ACTIVATING FACTOR
    CIRINO, G
    WALLACE, JL
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1989, 67 (01) : 72 - 74
  • [49] PLATELET-ACTIVATING FACTOR IN RENAL DISEASES
    CAMUSSI, G
    SALVIDIO, G
    TETTA, C
    AMERICAN JOURNAL OF NEPHROLOGY, 1989, 9 : 23 - 26
  • [50] Platelet-activating factor and oxidized LDL
    Androulakis, N
    Aronis, P
    Tsoukatos, DC
    FREE RADICAL RESEARCH, 2003, 37 : 77 - 77